VZW Cardiovascular Research Center Aalst
11
3
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
27%
3 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease
Role: collaborator
Early Aortic vaLve surgEry Versus wAtchful waitiNg Strategy in Severe Asymptomatic aOrtic reguRgitation
Role: collaborator
Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA
Role: lead
Evaluation of the Impact of Pulsed Field Ablation on Autonomic Nervous System Modulation in Paroxysmal Atrial Fibrillation
Role: lead
The Effect of Sublingual Nitroglycerin on Absolute Coronary Blood Flow
Role: lead
Pullback Pressure Gradient (PPG) Global Registry
Role: lead
Cardioprotective Effect of SGLT2-I in Diabetic Patients With AMI (SGLT2-I AMI PROTECT Study)
Role: collaborator
Novel Cardiac Imaging Prognostic Markers of Clinical Outcome in Patients With Chronic Aortic Regurgitation
Role: collaborator
Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE
Role: collaborator
Registry on Left Main Coronary Artery Bifurcation Percutaneous Intervention
Role: collaborator
Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation
Role: lead
All 11 trials loaded